Literature DB >> 3636335

A prospective randomized study comparing the efficacy of Timentin alone or in combination with amikacin in the treatment of febrile neutropenic patients.

J P Bru, M Michallet, C Legrand, P Swierz, J P Stahl, J B Leautet, J J Sotto, D Hollard, M Micoud.   

Abstract

One hundred febrile episodes in neutropenic (PMN less than 500/mm3) patients were treated with Timentin alone or in combination with amikacin. The overall response rate in 87 episodes was 82.9% with Timentin alone and 84.5% with the combination. Eleven out of 15 patients with septicaemia were cured by Timentin alone and 12 out of 13 by the combination, a response rate of 73.3% and 92.4% respectively (not-statistically significant P = 1.307). The rates of superinfection were low. Few side effects occurred. Timentin is a useful antibiotic in the treatment of febrile neutropenic patients and was, in this study, as effective alone as in combination with an aminoglycoside in the initial therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3636335     DOI: 10.1093/jac/17.suppl_c.203

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

2.  Antimicrobial stewardship program directed at broad-spectrum intravenous antibiotics prescription in a tertiary hospital.

Authors:  V C C Cheng; K K W To; I W S Li; B S F Tang; J F W Chan; S Kwan; R Mak; J Tai; P Ching; P L Ho; W H Seto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-09-01       Impact factor: 3.267

Review 3.  Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.

Authors:  Mical Paul; Yaakov Dickstein; Agata Schlesinger; Simona Grozinsky-Glasberg; Karla Soares-Weiser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.